Citation Impact
Citing Papers
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
2008
A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia
2018 StandoutNobel
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
2008
Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis
2008
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
2011
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Control of Regulatory T Cells by Co-signal Molecules
2019 StandoutNobel
Increased Thrombopoiesis and Platelet Activation in Hantavirus-Infected Patients
2015 StandoutNobel
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues
2009
Improving human hemato-lymphoid-system mice by cytokine knock-in gene replacement
2011
Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS‐T) a necessary or useful diagnostic category?
2008
Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors
2012
Thyroid cancer
2016 Standout
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
2007
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Gi-Coupled GPCR Signaling Controls the Formation and Organization of Human Pluripotent Colonies
2009 StandoutNobel
Regulation of chromatin by histone modifications
2011 Standout
Chemoattractants and their receptors in homeostasis and inflammation
2004
Cancer drug resistance: an evolving paradigm
2013 Standout
Targeting glutamine metabolism in myeloproliferative neoplasms
2015
Heterotrimeric G protein signaling: Role in asthma and allergic inflammation
2002
MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment
2007 Standout
Do phosphoinositide 3-kinases direct lymphocyte navigation?
2003
Central Role of RET in Thyroid Cancer
2013
The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder
2007 Standout
Preleukemia
2015
Vascular disorders of the liver # †
2008 Standout
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
2021
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
The chemokine system in diverse forms of macrophage activation and polarization
2004 Standout
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Basophils have emerged as a key player in immunity
2014
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
2008 StandoutNature
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Investigational Janus kinase inhibitors
2013
G protein-coupled receptors stimulation and the control of cell migration
2009
Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors
2020 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
TCR-mediated hyper-responsiveness of autoimmune G i2-/- mice is an intrinsic naive CD4+ T cell disorder selective for the G i2 subunit
2003
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
2009
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
The cancer stem cell: premises, promises and challenges
2011 Standout
Control of cell polarity and motility by the PtdIns(3,4,5)P3 phosphatase SHIP1
2006 StandoutNobel
Mammalian G Proteins and Their Cell Type Specific Functions
2005
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations
2019
Clinical pharmacokinetics of tyrosine kinase inhibitors
2009
TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
2013
Cancer-related inflammation and treatment effectiveness
2014 Standout
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
2009 Standout
β-Arrestin-2 regulates the development of allergic asthma
2003 StandoutNobel
Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis
2005
Cell signalling diversity of the Gqα family of heterotrimeric G proteins
2005
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
2020 StandoutNobel
The Many Roles of Chemokines and Chemokine Receptors in Inflammation
2006 Standout
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
2014
β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα
2004 StandoutNobel
Impaired TGF-β Responses in Peripheral T Cells of Gαi2−/− Mice
2005 StandoutNobel
Generation and Characterization of rgs5 Mutant Mice
2008
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
2015
Follicular Helper CD4 T Cells (TFH)
2011 Standout
mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent
2021 StandoutNobel
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C
2005 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment
2008
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Follicular Dendritic Cell Regulation of CXCR4-Mediated Germinal Center CD4 T Cell Migration
2004
Distinct Transcriptional Programs Activated by Interleukin-10 with or without Lipopolysaccharide in Dendritic Cells: Induction of the B Cell-Activating Chemokine, CXC Chemokine Ligand 13
2004
Cancer treatment and survivorship statistics, 2016
2016 Standout
New mutations and pathogenesis of myeloproliferative neoplasms
2011
Cancer treatment and survivorship statistics, 2019
2019 Standout
Myeloproliferative disorders
2008
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
β-Arrestin-2 regulates the development of allergic asthma
2003 StandoutNobel
Diagnosing and Managing Advanced Chronic Myeloid Leukemia
2015
Regulation of nuclear factor κB activation by G-protein-coupled receptors
2001
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
2015 Standout
The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS)
2006
Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
2009
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
2007
Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice
2013 StandoutNobel
IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
2011
Thrombocytosis: Diagnostic Evaluation, Thrombotic Risk Stratification, and Risk-Based Management Strategies
2011
An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia
2009
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Chemokines in Innate and Adaptive Host Defense : Basic Chemokinese Grammar for Immune Cells
2004
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of Éric Lippert being referenced
Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells
2011
Gα16 protein expression is up‐ and down‐regulated following T‐cell activation: disruption of this regulation impairs activation‐induced cell responses
1997
Metabolic Correction of Congenital Erythropoietic Porphyria with iPSCs Free of Reprogramming Factors
2012
The stem cell factor–c-KIT pathway must be inhibited to enable apoptosis induced by BCR–ABL inhibitors in chronic myelogenous leukemia cells
2009
RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation
2012
Leukemic blasts in transformed JAK2-V617F–positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
2007
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
2006
Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants
2011
Positive regulation of human T cell activation by Gi2 proteins and interleukin-8
2000
JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone
2012
A standardized endogenous megakaryocytic erythroid colony assay for the diagnosis of essential thrombocythemia.
2004
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
2011
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
2008
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity
2008
Interleukin-8 and Other Agonists of Gi2 Proteins: Autocrine Paracrine Growth Factors for Human Hematopoietic Progenitors Acting in Synergy with Colony Stimulating Factors
2000
Loss of the Y Chromosome in Philadelphia-Positive Cells Predicts a Poor Response of CML Patients to Imatinib Mesylate Therapy.
2008
Role of Regulator of G Protein Signaling 16 in Inflammation- Induced T Lymphocyte Migration and Activation
2003